RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer
A target trial emulation using the GEMCAD 14-01 prospective cohort
Maurel, J., Oliveres, H., Alonso, V., Feliu, J., Fernandez-Montes, A., Martin-Richard, M., Galvez, E., Ruiz-Casado, A., Yubero-Esteban, A., Aparicio, J., Alcaide, J., Gallego, J., Carmona, A., Fernandez-Martos, C., Sanchez, R. M. G., Manzano, H., Leno, R., Cuatrecasas, M., & De Albeniz, X. G. (2023). Upfront vs deferred monoclonal antibodies in metastatic colorectal cancer: A target trial emulation using the GEMCAD 14-01 prospective cohort. Journal of Clinical Oncology, 41(16).
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.